semaglutide for heart disease Obesity drug reduces risk of along with weight loss FDA approves weight-loss drug Wegovy

Further research may be needed to explore other potential predictors of weight change in these populations

They were given once-weekly doses of semaglutide (0.5 mg or 1.0mg) or a placebo for 104 weeks

Done right, research supports that the oral form is effective and has a safety profile comparable to the injection (a published review of the efficacy and safety of oral semaglutide)

These results are based on rodent research on mice that were affected by an Achilles tendon rupture

This is supported by in vitro evidence demonstrating that hyperglycemic conditions induce a proinflammatory phenotype in BV-2 microglia cells (Iannucci et al., 2022)